Physician profile
Wonhee Woo
NPI 1851824817
$2,024.85
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.40 · 2021: $1,103 · 2022: $880.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $381.80 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $327.00 | 2021-2022 | |
| Grifols USA, LLC | $207.16 | 2022 | |
| Pharming Healthcare, INC. | $195.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.25 | 2021-2022 | |
| Pfizer INC. | $128.98 | 2022 | |
| Biocryst US Sales Co., LLC | $109.55 | 2021 | |
| Genzyme Corporation | $105.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $93.07 | 2021 | |
| Horizon Therapeutics Plc | $86.70 | 2022 | |
| Genentech, INC. | $83.41 | 2022 | |
| Glaxosmithkline, LLC. | $72.04 | 2021 | |
| Baxter Healthcare | $62.53 | 2022 | |
| Kaleo, INC. | $23.56 | 2020 | |
| Csl Behring | $17.84 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonhee Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.